Clinical Trial Update: Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting eight weeks of Talnetant treatment in subjects with irritable bowel syndrome; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Talnetant (talnetant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Irritable Colon | Phase 2 | Status: COMPLETED